Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Laurence Buisseret"'
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) is a dose-finding phase I and a randomized phase II, open-label trial evaluating
Externí odkaz:
https://doaj.org/article/50f0c9a693404d0bbb0bf5ae3d4ee9c1
Autor:
Martine Piccart-Gebhart, Emanuela Romano, Christos Sotiriou, Marianne Paesmans, Ligia Craciun, Denis Larsimont, Roberto Salgado, Elisa Agostinetto, Laurence Buisseret, Isabelle Veys, Alex de Caluwé, Philip Poortmans, Andrea Gombos, Guilherme Nader Marta, Zoe Denis, Stylianos Drisis, Christophe Vandekerkhove, Antoine Desmet, Catherine Philippson, Dirk Van Gestel, Michail Ignatiadis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background Luminal B breast cancer (BC) presents a worse prognosis when compared with luminal A BC and exhibits a lower sensitivity to chemotherapy and a lower immunogenicity in contrast to non-luminal BC subtypes. The Neo-CheckRay clinical trial inv
Externí odkaz:
https://doaj.org/article/a5ee6654546a4d7e98521bceca85490a
Autor:
Véronique Debien, Alex De Caluwé, Xiaoxiao Wang, Martine Piccart-Gebhart, Vincent K. Tuohy, Emanuela Romano, Laurence Buisseret
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-10 (2023)
Abstract Recent progress in immunobiology has led the way to successful host immunity enhancement against breast cancer. In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with c
Externí odkaz:
https://doaj.org/article/7616f38e2956432d86f0f5dcf1473292
Autor:
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine Piccart-Gebhart
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/1872bd3c329443328fa10ee0e5e38651
Autor:
Alex De Caluwé, Laurence Buisseret, Philip Poortmans, Dirk Van Gestel, Roberto Salgado, Christos Sotiriou, Denis Larsimont, Marianne Paesmans, Ligia Craciun, Drisis Stylianos, Christophe Vandekerckhove, Fabien Reyal, Veys Isabelle, Daniel Eiger, Martine Piccart, Emanuela Romano, Michail Ignatiadis
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Residual breast cancer after neo-adjuvant chemotherapy (NACT) predicts disease outcome and is a surrogate for survival in aggressive breast cancer (BC) subtypes. Pathological complete response (pCR) rate, however, is lower for lum
Externí odkaz:
https://doaj.org/article/77e1e848595f46df8edd12cb7e91b490
Autor:
Iris Nederlof, Davide De Bortoli, Yacine Bareche, Bastien Nguyen, Michiel de Maaker, Gerrit K. J. Hooijer, Laurence Buisseret, Marleen Kok, Marcel Smid, Gert G. G. M. Van den Eynden, Arie B. Brinkman, Jan Hudecek, Jan Koster, Christos Sotiriou, Denis Larsimont, John W. M. Martens, Marc J. van de Vijver, Hugo M. Horlings, Roberto Salgado, Elia Biganzoli, Christine Desmedt
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-13 (2019)
Abstract Background Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker
Externí odkaz:
https://doaj.org/article/df66d169093c486b9266d412cddea9ab
Autor:
John Stagg, Anne-Marie Mes-Masson, Rejean Lapointe, Pamela Thebault, David Allard, Isabelle Cousineau, Yacine Bareche, Sandra Pommey, Mayra Carneiro, Laurence Buisseret, Pavel Chrobak, Laudine Communal, Simon C Robson, Diane Provencher
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Hydrolysis of extracellular ATP to adenosine (eADO) is an important immune checkpoint in cancer immunology. We here investigated the impact of the eADO pathway in high-grade serous ovarian cancer (HGSC) using multiparametric platforms.Meth
Externí odkaz:
https://doaj.org/article/79a64e0d29404bbdb5f83e93f3d2960a
Autor:
Bertrand Allard, Isabelle Cousineau, David Allard, Laurence Buisseret, Sandra Pommey, Pavel Chrobak, John Stagg
Publikováno v:
OncoImmunology, Vol 8, Iss 8 (2019)
The formation of new lymphatic vessels, or lymphangiogenesis, is a critical step of the tissue repair program. In pathological conditions involving chronic inflammation or tumorigenesis, this process is often dysregulated and can contribute to diseas
Externí odkaz:
https://doaj.org/article/4c6e80ae469f464d96f594cbcfcfdc21
Autor:
Soizic Garaud, Pawel Zayakin, Laurence Buisseret, Undine Rulle, Karina Silina, Alexandre de Wind, Gert Van den Eyden, Denis Larsimont, Karen Willard-Gallo, Aija Linē
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
An important role for tumor infiltrating B lymphocytes (TIL-B) in the immune response to cancer is emerging; however, very little is known about the antigen specificity of antibodies produced in situ. The presence of IgA antibodies in the tumor micro
Externí odkaz:
https://doaj.org/article/3eac83e6fde64c8eaab9b0557dac1c27
Autor:
Elisa Agostinetto, Guilherme Nader-Marta, Marianne Paesmans, Lieveke Ameye, Isabelle Veys, Laurence Buisseret, Patrick Neven, Donatienne Taylor, Christel Fontaine, Francois P Duhoux, Jean-Luc Canon, Hannelore Denys, Florence Coussy, Camille Chakiba, Joana Mourato Ribeiro, Martine Piccart, Christine Desmedt, Michail Ignatiadis, Philippe Aftimos
Publikováno v:
Future oncology (London, England), Vol. 18, no. 22, p. 2383-2392 (2022)
Invasive lobular carcinoma (ILC) is the most common histologic subtype of breast cancer after invasive ductal carcinoma (i.e., no special type [NST]). ILC differs from NST in clinical presentation, site-specific metastases and response to conventiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d419a7e09a61d7c0177b934038565de
https://doi.org/10.2217/fon-2022-0358
https://doi.org/10.2217/fon-2022-0358